跳到主要內容

臺灣博碩士論文加值系統

(3.229.142.104) 您好!臺灣時間:2021/07/27 05:15
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

: 
twitterline
研究生:趙雅嬋
研究生(外文):Ya-chan Chao
論文名稱:富含EGCG之綠茶萃取物對第2型糖尿病患慢性發炎及致血栓危險因子影響之探討
論文名稱(外文):Effect of EGCG-rich green tea extract (GTE) on chronic inflammation and thrombogenic risk factors in type 2 DM patients
指導教授:詹恭巨詹恭巨引用關係
指導教授(外文):Kung-chi Chan
學位類別:碩士
校院名稱:靜宜大學
系所名稱:食品營養研究所
學門:醫藥衛生學門
學類:營養學類
論文種類:學術論文
論文出版年:2010
畢業學年度:98
語文別:中文
論文頁數:99
中文關鍵詞:第2型糖尿病綠茶萃取物致血栓性慢性發炎兒茶素
外文關鍵詞:Type 2 diabetes mellitusGreen tea extractthrombogenic risk factorschronic inflammationEGCG
相關次數:
  • 被引用被引用:2
  • 點閱點閱:1121
  • 評分評分:
  • 下載下載:258
  • 收藏至我的研究室書目清單書目收藏:1
糖尿病(Diabetes Mellitus, DM)患者因高血糖所引起的氧化傷害易導致慢性併發症的發生。文獻指出,綠茶具有降血糖、抗氧化及抗發炎等功效,但其萃取物是否可降低DM患者致血栓之危險性仍須進一步的研究。因此,本研究目的為探討富含EGCG (Epigallocatechin-3-gallate)之綠茶萃取物(Green tea extract, GTE)對第2型糖尿病患血糖、慢性發炎及致血栓危險因子之影響。實驗分成DM對照組、DM給予低劑量GTE組(300mg/day)、DM給予中劑量GTE組(600mg/day)、DM給予高劑量GTE組(900mg/day),為期8週,於實驗前後分析血糖、胰島素、脂質過氧化物、發炎指標(hs-CRP、IL-6、TNF-α)、血管內皮細胞損傷指標(vWF)及凝血因子FVII、抗凝血因子AT- Ⅲ與Protein C、抗纖溶因子PAI-1等致血栓危險因子。結果顯示,給予糖尿病患8週GTE之補充有降低血糖、胰島素濃度及胰島素抗性之趨勢,其中高劑量GTE之給予可顯著降低血糖與HbA1c之濃度,血漿MDA也有降低之趨勢;GTE之補充有降低血漿hs-CRP、IL-6、TNF-α、vWF濃度、FVII活性及增加血漿抗凝血因子AT-III與PC活性之趨勢。綜合上述,綠茶萃取物(900mg/day)之給予,有助於糖尿病患控制血糖,具有減少脂質過氧化,延緩發炎及改善血管內皮細胞損傷之潛力,因而降低致血栓併發症之危險性。




關鍵字:第2型糖尿病、綠茶萃取物、兒茶素、慢性發炎、致血栓性
Hyperglycemia-induced oxidative damage plays an important role in the development of chronic complications in type 2 diabetic patients. The health benefits of green tea extract (GTE), including the antioxidative, hypoglycemic, and anti-inflammatory effects have been well-known. The purpose of this study was to investigate the effect of EGCG-rich GTE on chronic inflammation and thrombogenic risk factors in type 2 DM patients. Fifty-one type 2 DM patients were randomly assigned into four experimental groups in this double-blinded study. Treatment groups were placebo (300 mg/day cellulose), low GTE group (300 mg/day GTE), medium GTE group (600 mg /day GTE) and high GTE group (900 mg/day GTE), respectively. After 8 weeks’ supplement, concentration of fasting plasma glucose, HbA1c, MDA, von Willebrand factor and inflammatory markers, activity of coagulation factor, anticoagulation factors and fibrinolytic factor were measured. The results of this study showed that concentration of fasting glucose, HbA1c, MDA and activity of factor VII were decreased significantly (p<0.1) ; activity of AT-III were increased significantly (p<0.1) in high dose GTE group. Concentration of vWF were increased significantly (p<0.1) in placebo group, however, PAI-1 value was not affected by GTE supplement. Concentration of insulin, hs-CRP, IL-6, TNF-α, vWF and insulin resistance all tended to be decreased by GTE supplementation. In conclusion, supplementing 900 mg/day of EGCG-rich GTE may have beneficial effects to ameliorate oxidative stress, chronic inflammation, abnormal blood coagulation, and hence decrease thrombogenic risk in type 2 diabetic patients.

Keywords: Type 2 diabetes mellitus, Green tea extract, EGCG, chronic inflammation, thrombogenic risk factors
目錄
頁次
謝誌....................................................I
目錄.................................................... II
圖目錄.................................................. VI
表目錄.................................................. VII
中文摘要................................................VIII
英文摘要................................................ IX
縮寫對照表............................................... XI

第一章 前言............................................. 1
第二章 文獻回顧......................................... 3
第一節 糖尿病之簡介.................................. 3
一、 糖尿病之定義及診斷標準......................... 3
二、 糖尿病之分類................................... 4
三、 糖尿病之慢性併發症............................. 5
第二節 氧化壓力與糖尿病.............................. 7
一、 糖尿病患體內之氧化傷害......................... 7
二、 糖尿病患體內之抗氧化防禦系統................... 8
三、 高糖誘發氧化壓力之機制......................... 9
第三節 發炎反應與糖尿病.............................. 14
第四節 凝血機制與糖尿病.............................. 15
一、 凝血反應...................................... 15
二、 相關凝血因子................................... 19
三、 糖尿病患體內異常凝血系統之現象................. 21
第五節 綠茶與糖尿病.................................. 23
一、 綠茶之簡介.................................... 23
二、 綠茶素與糖尿病................................. 26
第六節 研究目的..................................... 28
第三章 材料與方法........................................ 29
第一節 實驗材料..................................... 29
第二節 人體試驗與試驗設計............................ 30
一、 受試者招募與篩選............................... 30
二、 試驗設計及進行步驟............................. 32
三、 抽血注意事項及血液樣品之前處理.................. 34
第三節 實驗分析方法.................................. 34
一、 血漿胰島素濃度分析............................. 34
二、 血漿丙二醛之濃度測定............................ 35
三、 發炎性指標分析................................. 36
四、 凝血與抗凝血功能及內皮細胞功能之測定............ 37
第四節 統計分析..................................... 41
第四章 結果............................................. 42
第一節 第2型糖尿病患受試者之基本資料................... 42
第二節 第2型糖尿病患受試者之生活型態及飲食習慣.......... 42
第三節 綠茶素之補充對第2型糖尿病患血糖、胰島素、胰島
素抗性及MDA濃度之影響.......................... 43
一、 綠茶素之補充對第2型糖尿病患血糖之影響................... 43
二、 綠茶素之補充對第2型糖尿病患糖化血色素之影響............. 43
三、 綠茶素之補充對第2型糖尿病患血漿胰島素濃度之影響.......... 43
四、綠茶素之補充對第2型糖尿病患胰島素抗性之影響.............. 44
五、 綠茶素之補充對第2型糖尿病患血漿MDA濃度之影響............ 44
第四節 綠茶素之補充對第2型糖尿病患體內發炎指標之影響..... 45
一、 綠茶素之補充對第2型糖尿病患血漿高敏感C反應蛋白 (hs-CRP)濃度之
影響................................................ 45
二、 綠茶素之補充對第2型糖尿病患血漿介白素-6 (IL-6)濃度之影響..45
三、 綠茶素之補充對第2型糖尿病患血漿腫瘤壞死因子- α(TNF-α)濃度之影
響................................................. 45
第五節 綠茶素之補充對第2型糖尿病患凝血與抗凝血功能及內皮細胞功
能之影響...................................... 46
一、 綠茶素之補充對第2型糖尿病患血漿凝血因子VII (FVII)活性之影
響................................................. 46
二、 綠茶素之補充對第2型糖尿病患血漿第三抗凝血酶(AT-III)活性之影
響................................................. 46
三、 綠茶素之補充對第2型糖尿病患血漿中蛋白C (Protein C)活性之影
響................................................. 47
四、 綠茶素之補充對第2型糖尿病患血漿纖溶酶原活化劑抑制因子-1(PAI-
1)濃度之影響.........................................47
五、 綠茶素之補充對第2型糖尿病患血漿von Willebrand Factor (vWF)
濃度之影響........................................... 48
第五章 討論............................................. 65
第一節 受試者基本資料之分析........................... 65
第二節 綠茶素之補充對第2型糖尿病患血糖、糖化血色素及胰島素濃度
之探討........................................ 66
第三節 綠茶素之補充對第2型糖尿病患血漿MDA濃度之探討..... 67
第四節 綠茶素之補充對第2型糖尿病患體內發炎指標濃度之探討..68
第五節 綠茶素之補充對第2型糖尿病患凝血與抗凝血功能、纖溶系統及
內皮細胞功能之探討............................. 69
一、 綠茶素之補充對第2型糖尿病患凝血與抗凝血功能之探討.........69
二、 綠茶素之補充對第2型糖尿病患內皮細胞功能之探討............ 72
第六章 結論............................................. 75
第七章 參考文獻......................................... 76
第七章 參考文獻

周先樂 (2000)。人體生理學。藝軒圖書出版社,台北。
何敏夫 (2002)。血液學。合計圖書出版社,台北。
吳亮宜,孫璐西。 茶與健康。 科學發展。 2004;384:18-23。
行政院衛生署(2010)衛生統計資訊網,中華民國98年死因統計,上卷http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx?now_fod_list_no=11122&class_no=440&level_no=3。
Abboud PA, Hake PW, Burroughs TJ, Odoms K, O''Connor M, Mangeshkar P, Wong HR, Zingarelli B. Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis. Eur. J. Pharmacol. 2008;28:411-7.
Abordo EA, Thornalley PJ. Synthesis and secretion of tumour necrosis factor-alpha by human monocytic THP-1 cells and chemotaxis induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts. Immunol. Lett. 1997;58:139-47.
Abou-Seif MA, Youssef AA. Evaluation of some biochemical changes in diabetic patients. Clin. Chim. Acta. 2004;346:161-70.
Acosta J, Hettinga J, Fluckiger R. Molecular basis for a link between complement and the vascular complications of diabetes. Proc. Natl. Acad. Sci. U S A. 2000;97:5450-5.
Aliciguzel Y, Ozen I, Aslan M, Karayalcin U. Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J. Lab. Clin. Med. 2003;142:172-7.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. 2007;30:S42-7.
Anderson RA, Polansky MM. Tea enhances insulin activity. J. Agric. Food. Chem. 2002;50:7182-6.
Arslantas A. Development of functional models for a SOD. Met. Based. Drugs. 2002;9:9-18.
Asakawa H, Tokunaga K, Kawakami F. Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. J. Diabetes. Complications. 2000;14:121-6.
Ashour M, Salem S, Hassaneen H, EL-Gadban H, Elwan N, Awad A, TK Basu. Antioxidant status and insulin dependent diabetes mellitus (IDDM). J. Clin. Biochem. Nutr. 1999;26:99-107.
Aso Y, Fujiwara Y, Tayama K. Elevation of von Willebrand factor in plasma in diabetic patients with neuropathic foot ulceration. Diab. Med. 2002;19:19-26.
Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia. 1993;36:817-25.
Avogaro A, Fadini GP, Gallo A. Endothelial dysfunction in type 2 diabetes mellitus. Nutr. Metab. Cardiovasc. Dis. 2006;16:S39-45.
Babu PV, Sabitha KE, Shyamaladevi CS. Therapeutic effect of green tea extract on oxidative stress in aorta and heart of streptozotocin diabetic rats. Chem. Biol. Interact. 2006;162:114-20.
Bagg W, Ferri C, Desideri G. The influences of obesity and glycemic control on endothelial activation in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2001;86:541-7.
Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine. Netw. 2006;17:4-12.
Beer S, Feihl F, Ruiz J, Juhan-Vague I, Aillaud MF, Wetzel SG, Liaudet L, Gaillard RC, Waeber B. Comparison of skin microvascular reactivity with hemostatic markers of endothelial dysfunction and damage in type 2 diabetes. Vasc. Health. Risk. Manag. 2008;4:1449-58.
Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: dose it exist ? Br. J. Haematol. 1995;90:244-8.
Blann AD, McCollum CN, Lip GY. Relationship between plasma markers of endothelial cell integrity and the Framingham cardiovascular disease risk-factor scores in apparently healthy individuals. Blood. Coagul. Fibrinolysis. 2002;13:513-8.
Bochkov VN, Mechtcheriakova D, Lucerna M, Huber J, Malli R, Graier WF, Hofer E, Binder BR, Leitinger N. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. Blood. 2002;99:199-206.
Boden B, Carnell LH. Nutritional effects of fat on carbohydrate metabolism. Best. Pract. Res. Clin. Endocrinol. Metab. 2003;14:71-7.
Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab 2007; 92:4352-8.
Borsey DQ, Prowse CV, Gray RS, Dawes J, James K, Elton RA, Clarke BF. Platelet and coagulation factors in proliferative diabetic retinopathy. J. Clin. Pathol. 1984;37:659-64.
Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA, Yang CS. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J. Nutr. 2008;138: 1677-83.
Bragt MC, Plat J, Mensink M, Schrauwen P, Mensink RP. Anti-inflammatory effect of rosiglitazone is not reflected in expression of NFkappaB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus. BMC Endocr Disord. 2009;9:8.
Brownlee M, Vlassara H, Cerami A. Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation. Possible role in fibrin deposition in diabetes. Diabetes. 1984;33:532-5.
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-20.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-25.
Bucala R, Cerami A. Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv. Pharm. 1992;23:1-4.
Cabrera C, Artacho R, Giménez R. Beneficial effects of green tea--a review. J. Am. Coll. Nutr. 2006;25:79-99.
Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr. Rev. 2001;2:36-52.
Camera M, Giesen PL, Fallon J, Aufiero BM, Taubman M, Tremoli E, Nemerson Y. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 1999;19:531-7.
Cao H, Hininger-Favier I, Kelly MA, Benaraba R, Dawson HD, Coves S, Roussel AM, Anderson RA. Green tea polyphenol extract regulates the expression of genes involved in glucose uptake and insulin signaling in rats fed a high fructose diet. J. Agric. Food Chem. 2007;55:6372-8.
Carr ME. Diabetes mellitus: a hypercoagulable state. J. Diabetes. Complications. 2001;15:44-54.
Ceriello A, Giugliano D, Quatraro A, Dello RP, Torella R. Blood glucose may condition factor VII levels in diabetes and normal subjects. Diabetologia. 1988;31:889-91.
Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol. 2004;24:816-23.
Cerriello A, Gugliano D, Quatraro A. Induced hyperglycaemia alters antithrombin III activity but not its plasma concentration in healthy normal subjects. Diabetes. 1987. 36:320-5.
Ceriello A, Giugliano D, Quatraro A, Marchi E, Barbanti M, Lefèbvre P. Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans. Diabetologia. 1990;33:163-7.
Chacko SM, Thambi PT, Kuttan R, Nishigaki I. Beneficial effects of green tea: a literature review. Chin. Med. 2010;5:13.
Chan V, Yeung CK, Chan TK. Antithrombin III and fibrinogen degradation product (fragment E) in diabetic nephropathy. J. Clin. Pathol. 1982;35:661-6.
Chan MM, Fong D, Ho CT, Huang HI. Inhibition of inducible nitric oxide synthase gene expression and enzyme activity by epigallocatechin gallate, a natural product from green tea. Biochem. Pharmacol. 1997;54:1281-6.
Chen J, Brodsky SV, Goligorsky DM, Hampel DJ, Li H, Gross SS. Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. Circ. Res. 2002;90:1290-8.
Choy CK, Rodgers JE, Nappi JM, Haines ST. Review of therapeutics: Type 2 diabetes mellitus and heart failure. Pharmacotherapy. 2008;28:170-192.
Churdchomjan W, Kheolamai P, Manochantr S, Tapanadechopone P, Tantrawatpan C, U-Pratya Y, Issaragrisil S. Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control. BMC Endocr Disord. 2010;10:5.
Collier A, Rumley A, Rumley AG, Paterson JR, Leach JP, Lowe GD, Small M. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes. 1992;41:909-13.
Colwell JA, Lyon TJ, Klein RL. Atherosclerosis and thrombosis in diabetes mellitus: new aspects of pathogenesis. In: Bowker JH, Pfeifer MA, editors. Levin and O’Neal’s The diabetic foot. 2001;65-106.
Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T. Oxidative damage to DNA in diabetes mellitus. Lancet. 1996;347:444-5.
De La Cruz JP, González-Correa JA, Guerrero A, de la Cuesta FS. Pharmacological approach to diabetic retinopathy. Diabetes. Metab. Res. Rev. 2004;20:91-113.
De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler. Thromb. Vasc. Biol. 2000;20:E83-8.
Del Prato S, Piero M, Riccardo CB. Phasic Insulin Release and Metabolic Regulation in Type 2 Diabetes. Diabetes. 2007;51:S109-16.
Di Mario U, Borsey DQ, Contreas G, Prowse CV, Clarke BF, Andreani D. The relationship of soluble immune complexes, insulin antibodies and insulin-anti-insulin complexes to platelet and coagulation factors in type 1 diabetic patients with and without proliferative retinopathy. Clin. Exp. Immunol. 1986;65:57-65.
Dominguez C, Ruiz E, Gussinye M, Carrascisa A. Oxidative stress at onset and in early stages of type I diabetes in children and adolescents. Diabetes. Care 1998;21:1736-42.
Donà M, Dell''Aica I, Calabrese F, Benelli R, Morini M, Albini A, Garbisa S. Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J. Immunol. 2003;170:4335-41.
Donnelly R, Emslie-Smith AM, Gardner ID, Morris AD. ABC of arterial and venous disease: vascular complications of diabetes. BMJ. 2000;320:1062-6.
Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites, J. Clin. Invest. 1980;65:128-135.
Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl. Acad. Sci. 2000;97:12222-6.
Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest. 2001;108:1341-8.
Du X, Matsumura T, Edelstein D, Rossetti L, Zsengellér Z, Szabó C, Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest. 2003;112:1049-57.
Ducrocq R, Bachour H, Belkhodja R, Berriche S, Elion J. Evidence for nonenzymic glycation of antithrombin III in diabetic patients. Clin. Chem. 1985;31:338-9.
Dunn EJ, Grant PJ. Type 2 diabetes: an atherothrombotic syndrome. Curr. Mol. Med. 2005;5:323-32.
Eckel RH, York DA, Rössner S, Hubbard V, Caterson I, St Jeor ST, Hayman LL, Mullis RM, Blair SN. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation. 2004;110:2968-75.
El-Mesallamy H, Suwailem S, Hamdy N. Evaluation of C-reactive protein, endothelin-1, adhesion molecule(s), and lipids as inflammatory markers in type 2 diabetes mellitus patients. Mediators. Inflamm. 2007;73635:1-7.
Erba D, Riso P, Criscuoli F, Testolin G. Malondialdehyde production in Jurkat T cells subjected to oxidative stress. Nutrition. 2003;19:545-8.
Esmon CT. The protein C pathway. Chest. 2003;124:26S-32S.
Faure P, Benhamou PY, Perard A, Halimi S, Roussel AM. Lipid peroxidationin insulin dependent diabetic patients with early retina degenerative lesions: Effects of an oral zinc supplementation. Eur. J. Clin. Nutr. 1995;49:282-8.
Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, Lauro D. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation. 2002;106:466-72.
Feener EP, Xia P, Inoguchi T, Shiba T, Kunisaki M, King GL. Role of protein kinase C in glucose- and angiotensin II-induced plasminogen activator inhibitor expression. Contrib. Nephrol. 1996;118:180-7.
Festa A, D’Agostino R Jr, Mykkanen L. The Insulin Resistance Atherosclerosis Study (IRAS). Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. Arterioscler. Thromb. Vasc. Biol. 1999;19:562-8.
Fonseca VA, Theuma P, Mudaliar S, Leissinger CA, Clejan S, Henry RR. Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. J. Diabetes. Complications. 2006;20:14-20.
Garibaldi S, Aragno I, Odetti P, Marianari UM. Relationships between protein carbonyls, retinol, and tocopherols levels in human plasma. Biochem. Mol. Biol. Int. 1994;34:729-36.
Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J. Clin. Invest. 1994;94:110-7.
Glogowski EA, Tsiani E, Zhou X, Fantus IG, Whiteside C. High glucose alters the response of mesangial cell protein kinase C isoforms of endothelin-1. Kidney. Int. 1999;55:486-99.
Groot H, Rauen U. Tissue injury by reactive oxygen species and the protective effects of flavonoids. Fund. Clin. Pharmacol. 1998;12:249-55.
Gordon PA. Effects of diabetes on the vascular system: current research evidence and best practice recommendations. J. Vasc. Nurs. 2004;22:2-11.
Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell. Biol. 2008;9:367-77.
Haidara MA, Khloussy H, Ammar H, Aal Kassem LA. Impact of alpha-tocopherol and vitamin C on endothelial markers in rats with streptozotocin-induced diabetes. Med. Sci. Monit. 2004;10:41-6.
Halliwell B. Antioxidants and human disease: a general introduction. Nutr. Rev. 1997;55:44-52.
Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
Hayden MS, West AP, Ghosh S. NF-kappa B and the immune response. Oncogene. 2006;25:6758-80.
He M, He X, Xie Q, Chen F, He S. Angiotensin II induces the expression of tissue factor and its mechanism in human monocytes. Thromb. Res. 2006;117:579-90.
Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem. J. 1990;265:621-36.
Herkert O, Diebold I, Brandes RP, Hess J, Busse R, Gorlach A. NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells. Circulation. 2002;105:2030-6.
Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit. Rev. Food. Sci. Nutr. 2003;43:89-143.
Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT. A central role for JNK in obesity and insulin resistance. Nature. 2002;420:333-6.
Ho FM, Liu SH, Liau CS, Huang PJ, Lin-Shiau SY. High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation. 2000;101:2618-24.
Ho FM, Lin WW, Chen BC, Chao CM, Yang CR, Lin LY. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cell. Signal. 2006;18:391-9.
Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 1995;95:2409-15.
Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF. IRS-1- mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity-induced insulin resistance. Science. 1996;271:665-8.
Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49:1939-45.
Isbrucker RA, Edwards JA, Wolz E, Davidovich A, Bausch J. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies. Food. Chem. Toxicol. 2006;44:636-50.
Iso H, Date C, Wakai K, Fukui M, Tamakoshi A. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Ann. Intern. Med. 2006;144:554-62.
Izaguirre G, Swanson R, Raja SM, Rezaie AR, Olson ST. Mechanism by which exosites promote the inhibition of blood coagulation proteases by heparin-activated antithrombin. J. Biol. Chem. 2007;282:33609-22.
Jain SK, Mc Vie R. Effect of glycemic control race (white vs black) and duration of diabetes on reduced glutathion content in erythrocytes of diabetic patients. Metabolism. 1994;43:306-9.
Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death [see comments]. Br. Heart. J. 1991;66:351-5.
Jarvisalo MJ, Harmoinen A, Hakanen M, Paakkunainen U, Viikari J. Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler. Thromb. Vasc. Biol. 2002;22:1323-8.
Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin. Thromb. Haemost. 1989;61:370-3.
Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann. Med. 1996;28:371-80.
Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb. Haemost. 1997;78:656-60.
Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840-6.
Kalousová M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol. Res. 2002;51:597-604.
Kaneko T, Matsuo M, Baba N. Inhibition of linoleic acid hydroperoxide induced toxicity in cultured human umbilical vein endothelial cells by catechins. Chem. Biol. Interact. 1998;114:109-19.
Kang WS, Chung KH, Chung JH, Lee JY, Park JB, Zhang YH, Yoo HS, Yun YP. Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase. J. Cardiovasc. Pharmacol. 2001;38:875-84.
Kannel WB, Wolf PA, Castelli WP. Fibrinogen and risk of cardiovascular disease: The Framingham Study. JAMA. 1987;258:1183-6.
Katiyar SK, Matsui MS, Elmets CA, Mukhtar H. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea reduces UVB-induced inflammatory responses and infiltration of leukocytes in human skin. Photochem. Photobiol. 1999;69:148-53.
Kathiresan S, Gona P, Larson MG. Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation. 2006;113:938-45.
Kawamura N, Ookawara T, Suzuki K, Konishi K, Mino M, Taniguchi NC. Increased glycated Cu, Zn superoxide dismutase levels in erythrocytes of patients with insulin dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1992;74:1352-4.
Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2001;280: E745-51.
Kessler L, Wiessel ML, Attali P, Mossard JM, Cazenace JP, Pingent M. von Willebrand factor in diabetic angiopathy. Diabetes Metab. 1998;24:327-38.
Kim S, Lee MJ, Hong J. Plasma and tissue levels of tea catechins in rats and mice during chronic consumption of green tea polyphenols. Nutr Cancer 2000;37:41-8.
Kim JH, Kang BH, Jeong JM. Antioxidant antimutagenic and chemopreventive activities of a phyto-extract mixture derived from various vegetables, fruits and oriental herbs. Food. Sci. Biotechnol. 2003;12:631-8.
Kim JA, Tran ND, Berliner JA, Fisher MJ. Minimally oxidized low-density lipoprotein regulates hemostasis factors of brain capillary endothelial cells. J. Neurol. Sci. 2004;217:135-41.
Kimberly MM, Cooper GR, Myers GL. An overview of inflammatory markers in type 2 diabetes from the perspective of the clinical chemist. Diabetes. Technol. Ther. 2006;8:37-44.
Koc M, Karaarslan O, Abali G, Batur MK. Variation in high-sensitivity C-reactive protein levels over 24 hours in patients with stable coronary artery disease. Tex. Heart. Inst. J. 2010;37:42-8.
Konieczkowski M, Skrinska VA. Increased synthesis of thromboxane A(2) and expression of procoagulant activity by monocytes in response to arachidonic acid in diabetes mellitus. Prostaglandins. Leukot. Essent. Fatty Acids. 2001;65: 133-8.
Korshunov SS, Skulachev VP, Starkov AA. High protonic potential actuatesa mechanism of production of reactive oxygen species in mitochondria. FEBS Lett. 1997;416:15-8.
Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859-66.
Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest. 1997;100:115-26.
Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo : a specific vascular action of insulin. Circulation. 2000;101:676-81.
Laasko M, Lehto S. Epidemiology of macrovascular disease in diatetes. Diab. Rev. 1997;5:294-315.
Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937-42.
Lau D, Yan H, Abdel-Hafez M, Kermouni A. Adipokines and the paracrine control of their production in obesity and diabetes. Int. J. Obes. Relat. Metab. Disord. 2002;26:S111. Abstrace.
Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB. J. 1999;13:23-30.
Leopold JA, Loscalzo J. Oxidative risk for atherothrombotic cardiovascular disease. Free. Radic. Biol. Med. 2009;47:1673-706.
Leurs PB, Stolk RP, Hamulyak K. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes. Care. 2002; 25:1340-5.
Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation. 2001;103:1718-20.
Limaye PV, Raghuram N, Sivakami S. Oxidative stress and gene expression of antioxidant enzymes in the renal cortex of streptozotocin-induced diabetic rats. Mol. Cell. Biochem. 2003;243:147-52.
Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003;169:203-14.
Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S, Llampayas O, Badimon L. Aggregated lowdensity lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation. 2004;110:452-9.
Mansfield MW, Heywood DM, Grant PJ. Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 1996;16:160-4.
Matés JM, Sánchez-Jiménez F. Antioxidant enzymes and their implications in pathophysiologic processes. Front. Biosci. 1999;4:D339-45.
Matsumoto N, Ishigaki F, Ishigaki A, Iwashina H, Hara Y. Reduction of blood glucose levels by tea catechin. Biosci., Biotechnol., Biochem. 1993;57: 525-7.
Mazer SP, Rabbani LE. Evidence for C-reactive protein’s (CRP) role in vascular disease. atherothrombosis, immuno-regulation and CRP. J. Thromb. 2004;17:95-105.
Mazzone T, Chait A, Plutsky J. Cardiovascular disease risk in type 2 diabetes mellitus: Insights from mechanistic studies. Lancet. 2008;371:1800-9.
McGill JB, Schneider DJ, Arfken CL. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994;43:104-9.
McKay DL, Blumberg JB. The role of tea in human health: An update. J. Am. Coll. Nutr. 2002;21:1-13.
Mohamed-Ali V, Goodrisk S, Rawesh A. Subcutaneous adipose tissue releases interleukin-6 but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocr. Metab. 1997;82:4196-200.
Mooradian AD, Failla M, Hoogwerf B, Maryniuk M, Wylie-Roset J. Selected vitamins and minerals in diabetes. Diabetes. Care. 1994;5:464-78.
Mustata GT, Rosca M, Biemel KM, Reihl O, Smith MA, Viswanathan A, Strauch C, Du Y, Tang J, Kern TS, Lederer MO, Brownlee M, Weiss MF, Monnier VM. Paradoxical effects of green tea (Camellia sinensis) and antioxidant vitamins in diabetic rats: improved retinopathy and renal mitochondrial defects but deterioration of collagen matrix glycoxidation and cross-linking. Diabetes. 2005;54:517-26.
Nakagawa K, Ninomiya M, Okubo T, Aoi N, Juneja LR, Kim M, Yamanaka K, Miyazawa T. Tea catechin supplementation increases antioxidant capacity and prevents phospholipid hydroperoxidation in plasma of humans. J. Agric. Food.Chem. 1999;47:3967-73.
Nilsson T, Mellbring G, Hedner U. Relationship between factor XII, von Willebrand factor and postoperative deep vein thrombosis. Acta. Chir. Scand. 1986;152:347-9.
Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, Tritschler H, Rosen P, Halliwel B, Betteridge DJ. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologica. 1997;40:647-63.
Okushio K, Matsumoto N, Kohri T, Suzuki M, Nanjo F, Hara Y. Absorption of tea catechins into rat portal vein. Biol. Pharm. Bull. 1996;19:326-9.
Omoigui S. The Interleukin-6 inflammation pathway from cholesterol to aging--role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases. Immun. Ageing. 2007;4:1.
Pan HZ, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br. J. Ophthalmol. 2008;92:548-51.
Pandolfi A, Cetrullo D, Polishuck R. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler. Thromb. Vasc. Biol. 2001;21:1378-82.
Pasaoglu H, Sancak B, Bukan N. Lipid peroxidation and resistance to oxidation in patients with type 2 diabetes mellitus. Tohoku. J. Exp. Med. 2004;203:211-8.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes. Care. 2004;27:813-23.
Pfutzner A, Standl E, Strotmann HJ, Schulze J, Hohberg C, Lubben G, Pahler S, Schondorf T, Forst T. Association of high-sensitive Creactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus. Clin. Chem. Lab. Med. 2006;44:556-60.
Pitsavos C, Tampourlou M, Panagiotakos DB, Skoumas Y, Chrysohoou C, Nomikos T, Stefanadis C. Association between low-grade systemic inflammation and type 2 diabetes mellitus among men and women from the ATTICA Study. Rev. Diabet. Stud. 2007;4:98-104.
Polidori MC, Mecocci P, Stahl W, Parente B, Cecchetti R, Cherubini A, Cao P, Sies H, Senin U. Plasma levels of lipophilic antioxidants in very old patients with type 2 diabetes. Diabetes. Metab. Res. Rev. 2000;16:15-9.
Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM. C-Reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler. Thromb. Vasc. Biol. 2003;23:650-5.
Ramakrishna V, Jailkhani R. Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta. Diabetol. 2008;45:41-6.
Richardson A, Adner N, Nordstrom G. Persons with insulin-dependent diabetes mellitus: acceptance and coping ability. J. Adv. Nurs. 2001;33:758-63.
Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149-53.
Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-9.
Rigla M, Wagner AM, Borrell M. Postprandial thrombin activatable fi brinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients. Metab. 2006;55:1437-42.
Rizvi SI, Zaid MA, Anis R, Mishra N. Protective role of tea catechins against oxidation-induced damage of type 2 diabetic erythrocytes. Clin. Exp. Pharmacol. Physiol. 2005;32:70-5.
Roghani M, Baluchnejadmojarad T. Hypoglycemic and hypolipidemic effect and antioxidant activity of chronic epigallocatechin-gallate in streptozotocin-diabetic rats. Pathophysiology. 2010;17:55-9.
Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999;340:115-26.
Rutter K, Sell DR, Fraser N, Obrenovich M, Zito M, Starke-Reed P, Monnier VM. Green tea extract suppresses the age-related increase in collagen crosslinking and fluorescent products in C57BL/6 mice. Int. J. Vitam. Nutr. Res. 2003;73:453-60.
Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell. Biol. 1988;4:93-126.
Salomaa V, Matei C, Aleksic N. Atherosclerosis Risk in Communities. Cross-sectional association of soluble thrombomodulin with mild peripheral artery disease; the ARIC study. Atherosclerosis. 2001;157:309-14.
Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J. Clin. Invest. 1996;97:37-46.
Samad F, Yamamoto K, Pandey M, Loskutoff DJ. Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med. 1997;3:37-48.
Savill JS, Whyllie A, Henson J, Walport M, Henson P, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil lead to its recognition by macrophages. J. Clin. Invest. 1989; 83:865-75.
Schnedl WJ, Liebminger A, Roller RE, Lipp RW, Krejs GJ. Hemoglobin variant and determination of glycated hemoglobin(HbA1c). Diabetes. Metab. Res. Rev. 2001;17:94-8.
Seghieri G, Di Simplicio P, De Giorgio LA, Anichini R, Alberti L, Franconi F. Relationship between metabolic glycaemic control and platelet contenty of glutathione and its related enzymes, in insulin-dependent diabetes mellitus. Clin. Chem. Acta. 2000;299:109-11.
Seghrouchni I, Drai J, Bannier E, Rivière J, Calmard P, Garcia I, Orgiazzi J, Revol A. Oxidative stress parameters in type I, type II and insulin-treated type 2 diabetes mellitus; insulin treatment efficiency. Clin. Chim. Acta. 2002;321:89-96.
Shechter M, Merz CN, Paul-Labrador MJ. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J. Am. Coll. Cardiol. 2000;35:300-7.
Shen L, He X, Dahlbäck B. Synergistic cofactor function of factor V and protein S to activated protein C in the inactivation of the factor VIIIa - factor IXa complex -- species specific interactions of components of the protein C anticoagulant system. Thromb. Haemost. 1997;78:1030-6.
Shimada K, Kobayashi M, Kimura S, Nishinaga M, Takeuchi K, Ozawa T. Anticoagulant heparin-like glycosaminoglycans on endothelial cell surface. Jpn. Circ. J. 1991;55:1016-21.
Shin HY, Kim SH, Jeong HJ, Kim SY, Shin TY, Um JY, Hong SH, Kim HM. Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NF-kappa B in HMC-1 cells. Int. Arch. Allergy. Immunol. 2007;142:335-44.
Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, Brownlee M. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J. Clin. Invest. 1998;101:1142-7.
Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J. Clin. Invest. 2006;116:1793-1801.
Skrha J, Hodinar A, Kvosnicka J, Hilgertova J. Relationship of oxidative stress and fibrinolysis in diabetes mellitus. Diabet. Med. 1996;13:800-5.
Skrzydlewsja E, Augustyniak A, Ostrowska J, Luczaj W, Tarasiuk E. Green tea protection against aging-induced oxidative stress. Free. Radic. Biol. Med. 2002;33:555.
Slatter DA, Bolton CH, Bailey AJ. The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia. 2000;43:550-7.
St Onge EL, Motycka CA, Miller SA. A review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus. P. T. 2009;34:368-78.
Steppich BA, Braun SL, Stein A, Demetz G, Groha P, Schömig A, von Beckerath N, Kastrati A, Ott I. Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction. Thromb. J. 2009;7:11.
Studer RK, Craven PA, Derubertis FR. Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes. 1993;42:118-26.
Sueoka N, Suganuma M, Sueoka E, Okabe S, Matsuyama S, Imai K, Nakachi K, Fujiki H. A new function of green tea: prevention of lifestyle-related diseases. Ann. N. Y. Acad. Sci. 2001;928:274-80.
Takeuchi M, Yanase Y, Matsuura N, Yamagishi Si S, Kameda Y, Bucala R, Makita Z. Immunological detection of a novel advanced glycation end-product. Mol. Med. 2001;7:783-91.
Tanaka T, Itoh H, Doi K, Fukunaya Y, Hosada K, Shintani M, Yamashita J, Chun TH, Inoue M, Masatsugu K. Down regulation of peroxisome proliferator-activated receptor γ expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia. 1999;42:702-10.
Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem. 2000;275:25781-90.
Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet. Med. 2005;22:999-1004.
The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977-86.
Tian J, Chen JH, Li Q, He Q, Lin WQ. Lipid peroxidation in IgA nephropathy and the effect of lipo-prostaglandin E1. J. Nephrol. 2005;18:243-8.
Tsukushi S, Katsuzaki T, Aoyama I, Takayama F, Miyazaki T, Shimokata K, Niwa T. Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: role of the polyol pathway. Kidney. Int. 1999;55:1970-6.
Tsuneki H, Ishizuka M, Terasawa M, Wu JB, Sasaoka T, Kimura I. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. BMC. Pharmacol. 2004;4:18-21.
Ueki K, Kondo T, Tseng YH, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. U S A. 2004;101:10422-7.
UK prospective diabetes Study (UKPDS) Group. Effect of intensive blood-sugar control with sulphonyluria on complications in overweight patients with type 2 diabetes. Lancet. 1998;352:837-53.
Upchurch Jr GR, Ramdev N, Walsh MT, Loscalzo J. Prothrombotic Consequences of the Oxidation of Fibrinogen and their Inhibition by Aspirin. J. Thromb. Thrombolysis. 1998;5:9-14.
Valencia JV, Mone M, Zhang J, Weetall M, Buxton FP, Hughes TE. Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. Diabetes. 2004;23:743-51.
Vulin AI, Stanley FM. Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. J. Biol. Chem. 2004;279:25172-8.
Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 2006;160:1-40.
Vander Poll T, Levi M, Van Deventer JH. Tumor necrosis factor and the disbalance between coagulant and anticoagulant mechanisms in septicemia. in: Vincent JL, ed Update in intensive care and emergency medicine. Berlin. Springer.Verlag. 1991:269-73
van Doorn M, Kemme M, Ouwens M, van Hoogdalem EJ, Jones R, Romijn H, de Kam M, Schoemaker R, Burggraaf K, Cohen A. Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. Br. J. Clin. Pharmacol. 2006;62:391-402.
Vaughan D. PAI-1 and atherothrombosis. Journal of Thrombosis. and Haemostasis. 2005;3:1879-83.
Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105:546-9.
Vitale C, Cerquetani E, Wajngarten M, Leonardo F, Silvestri A. In patients with coronary artery disease endothelial function is associated with plasma levels of C-reactive protein and is improved by optimal medical therapy. Ital. Heart. J. 2003;4:627-32.
Vlassara H, Brownlee M, Manogue KR. Cachectin/ TNF and IL-1 induced by glucose-modified proteins; role in normal tissue remodeling. Science. 1988;240:1546-8.
Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 2001;280:E685-94.
Waltner-Law ME, Wang XL, Law BK, Hall RK, Nawano M, Granner DK. Epigallocatecin gallate, a constituent of green tea, represses hepatic glucose production. J. Biol. Chem. 2002;277:34933-40.
Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry. 1995;34:3702-9.
Wolfram S, Raederstorff D, Preller M, Wang Y, Teixeira SR, Riegger C, Weber P. Epigallocatechin gallate supplementation alleviates diabetes in rodents. J. Nutr. 2006;136:3512-8.
Wu LY, Juan CC, Hsu YP, Hwang LS. Effect of tea green supplementation on insulin sensitivity in Sprague-Dawley rats. J. Agric. Food. Chem. 2004;52:643-8.
Xanthis A, Hatzitolios A, Koliakos G, Tatola V. Advanced glycosylation end products and nutrition--a possible relation with diabetic atherosclerosis and how to prevent it. J. Food. Sci. 2007;72:R125-9.
Xu JZ, Yeung SY, Chang Q, Huang Y, Chen ZY. Comparison of antioxidant activity and bioavailability of tea epicatechins with their epimers. Br. J. Nutr. 2004;91:873-81.
Xu J, Qu D, Esmon NL. Metalloproteolytic release of endothelial cell protein C receptor. J. Biol. Chem. 2000;275:6038-44.
Yamimoto T, Juneja LR, Djoing-Chu C, Kim M. Chemistry and Applications of Green Tea. Boca. Raton. FL: CRC Press. 1997;51-52.
Yang CS, Chen L, Lee MJ, Balentine D, Kuo M, Schantz SP. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer. Epidemiol. Biomarkers. Prev. 1998;7:351-4.
Yang JA, Choi JH, Rhee SJ. Effects of green tea catechin on phospholipase A2 activity and antithrombus in streptozotocin diabetic rats. J. Nutr. Sci. Vitaminol. 1999;45:337-46.
Yang CS, Landau JM, Huang MT, Newmark HL. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu. Rev. Nutr. 2001;21:381-406.
Yang F, Oz HS, Barve S, de Villiers WJ, McClain CJ, Varilek GW. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol. Pharmacol. 2001;60:528-33.
Yildirim O, Buyukbingol Z. Effect of cobalt on the oxidative status in heart and aorta of streptozotocin-induced diabetic rats, Cell Biochem. Funct. 2003;21:27-33.
Yokoi T, Fukuo K, Yasuda O, Hotta M, Miyazaki J, Takemura Y. Apoptosis signal-regulating kinase 1 mediates cellular senescence induced by high glucose in endothelial cells. Diabetes. 2006;55:1660-5.
Zhang ZF, Li Q, Liang J, Dai XQ, Ding Y, Wang JB, Li Y. Epigallocatechin-3-Ogallate (EGCG) protects the insulin sensitivity in rat L6 muscle cells exposed to dexamethasone condition. Phytomedicine. 2010;17: 14-8.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top